Opus Genetics Inc

R3X1

Company Profile

  • Business description

    Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.

  • Contact

    8 Davis Drive
    Suite 220
    DurhamNC27713
    USA

    T: +1 984 884-6030

    https://www.opusgtx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    28

Stocks News & Analysis

stocks

After earnings, is Microsoft a buy, a sell, or fairly valued?

With third-quarter results surpassing even high-end expectations, here’s what we think of Microsoft stock.
stocks

Albemarle earnings: Shares rally on strong profit growth well above consensus estimates

Albemarle should see sequential profit growth in the second quarter and maintain higher profits through the year.
stocks

Ahead of IPOs, AI giants keep making circular deals. Here’s why that’s a risk

With OpenAI reportedly missing revenue targets, the imbalanced risks of circular deals become clearer.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,980.5031.60-0.35%
CAC 408,112.5789.51-1.09%
DAX 4024,338.63324.98-1.32%
Dow JONES (US)49,609.1612.190.02%
FTSE 10010,233.0743.88-0.43%
HKSE26,393.71232.57-0.87%
NASDAQ26,247.08440.881.71%
Nikkei 22562,713.65120.19-0.19%
NZX 50 Index13,175.1395.48-0.72%
S&P 5007,398.9361.820.84%
S&P/ASX 2008,744.4036.40-0.41%
SSE Composite Index4,179.950.14-0.00%

Market Movers